Health Care/Hospital

SN BioScience received US FDA Orphan Drug Designation for its Nano Anti-Cancer Drug 'SNB-101' on Gastric Cancer.

SEONGNAM, South Korea, Dec. 23, 2025 /PRNewswire/ -- SN Bioscience Inc. (CEO Young Hwan PARK) announced that the FDA had granted Orphan Drug Designation (ODD) onDecember 10 for gastric cancer (including gastroesophageal junction cancer) to SNB-101 (API: SN-38) which is a polymer nanoparticle drug...

2025-12-24 07:37 1868

NAVER D2SF-Backed Startups Participate in "CES 2026"

* Five teams won CES Innovation Awards, including one Best of Innovation Award and three double Innovation Award winners * Proving technological capabilities on the global stage across diverse sectors, including mobility, vertical AI, and healthcare * Over 80% of portfolio companies targetin...

2025-12-24 00:00 3780

Puainta Smashes Black Friday Records and Marks Successful Entry into UK Market

LOS ANGELES, Dec. 22, 2025 /PRNewswire/ -- Puainta, a rapidly growing innovator in pet healthcare and wellness, today announced significant milestones following the 2025 Black Friday sales event. The brand reported an unprecedented surge in global sales, a successful strategic expansion into the ...

2025-12-24 00:00 2222

Senhwa Biosciences Highlights AI-Validated Oncology Platform and Strategic Clinical Collaborations Targeting Next-Generation Immuno-Oncology products at Its 2025 Annual Investor Conference

TAIPEI and SAN DIEGO, Dec. 23, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical stage companies focusing on development of first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today outlined continued progress across its AI-enabled drug developm...

2025-12-23 20:00 3536

Fapon Biopharma Publishes Pioneering Research in Cell Reports Medicine on FP008, an anti-PD 1 X IL-10M Fusion Protein for Cancer Immunotherapy

DONGGUAN, China, Dec. 23, 2025 /PRNewswire/ -- Fapon Biopharma, a biotech in developing therapeutic biologics including cytokine-antibody fusion proteins and T-cell engagers, announced the publication of pioneering research on FP008, a novel fusion protein inCell Reports Medicine. The peer-review...

2025-12-23 13:03 2831

MCB Group Unveils Daily Sports Nutrition Innovations at SupplySide Global 2025, Spotlighting Creatine, MCT, and Plant-Based Protein

TAIPEI, Dec. 22, 2025 /PRNewswire/ -- MCB Group, a Taiwan-based global manufacturer ofpremium nutritional powder ingredients , has further streamlined its operations intoa full CDMO private-label provider , showca...

2025-12-22 22:00 3373

Kazia Therapeutics Regains Full Nasdaq Listing Compliance

Restoration of Nasdaq compliance follows $50 million institutional financing and reinforces balance-sheet strength SYDNEY, Dec. 22, 2025 /PRNewswire/ -- Kazia Therapeutics Limited ("Kazia" or the "Company") (NASDAQ: KZIA), a clinical-stage oncology company focused on developing innovative therap...

2025-12-22 21:00 6376

AI Platform to Combat Muscle Loss and Preserve Metabolic Vitality for GLP-1 Users

Livelively USA combines AI insights with Eastern wellness principles to support healthier long-term weight management behaviors. NEW YORK, Dec. 22, 2025 /PRNewswire/ -- Weight-loss medications are reshaping global healthcare, with the anti-obesity drug market projected to approach$100 billion by...

2025-12-22 21:00 1604

T-MAXIMUM Pharmaceutical's Allogeneic CAR-T Therapy MT027 Receives FDA IND Clearance to Proceed to Phase II clinical Trial for Recurrent Glioblastoma

BEIJING, Dec. 21, 2025 /PRNewswire/ -- T-MAXIMUM Pharmaceutical announced that its proprietary allogeneic, B7-H3-targeted CAR-T therapy, MT027, has received IND Clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase II clinical trial for the treatment of recurrent glioblas...

2025-12-21 20:20 2657

Jacobio Pharma Enters Global Exclusive License Agreement with AstraZeneca for Pan-KRAS Inhibitor JAB-23E73

BEIJING, SHANGHAI and BOSTON, Dec. 21, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK,) today announced that it has entered an agreement with AstraZeneca for its proprietary Pan-KRAS inhibitor JAB-23E73. AstraZeneca will receive exclusive development and commercialisation rights outside ofChina, wh...

2025-12-21 20:15 2925

Tokyo Lifestyle Co., Ltd. Reports First Six Months of Fiscal Year 2026 Financial Results

Revenue Increased by 94.3% YoY; Gross Profit Increased by 29.8% YoY TOKYO, Dec. 19, 2025 /PRNewswire/ -- Tokyo Lifestyle Co., Ltd. ("Tokyo Lifestyle" or the "Company") (Nasdaq: TKLF), a retailer and wholesaler of Japanese beauty and health products, sundry products, luxury products, electronic p...

2025-12-20 05:05 8940

Ceretone Showcases Core One Pro -- The Nearly Invisible OTC Hearing Aid -- at CES 2026

Ceretone invites CES attendees to experience its latest penny-sized, feather-light hearing solution and complimentary hearing tests at Booth #54619 LAS VEGAS, Dec. 19, 2025 /PRNewswire/ -- Ceretone , a consumer health technology company dedicated to making quality hearin...

2025-12-20 02:00 3617

Woori IO Shareholders Approve Share Exchange to Become Wholly-Owned Subsidiary of OSR Holdings

Company advancing dual clinical pathways, including a Samsung-supported PoC trial in Korea and a planned U.S. FDA trial with a leadingCalifornia research university BELLEVUE, Wash., Dec. 19, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH) ("OSR Holdings"), a global healthcare holding comp...

2025-12-20 00:50 8044

VARON Enhances Customer Access to Oxygen Concentrators Through Its Official Online Store

NEW YORK, Dec. 19, 2025 /PRNewswire/ -- As more individuals, families, and caregivers research oxygen therapy solutions online, knowingwhere to buy a reliable oxygen concentrator has become an important part of the decision-making process. With increasing demand for clear product information, au...

2025-12-19 19:52 3275

WuXi Biologics Achieves CDP Highest "A" Ratings in Both Climate Change and Water Security

SHANGHAI, Dec. 19, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK) announced that it has been named to the CDP "A" lists for both Climate Change and Water Security for 2025, underscoring its leadership in environmental stewardship and transparent disclosure. Climate Change Leadership Being recogn...

2025-12-19 17:30 5136

NEW DRUG APPLICATION FOR TINENGOTINIB TABLETS ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

NANJING, China and GAITHERSBURG, Md., Dec. 18, 2025 /PRNewswire/ -- TransThera Sciences Nanjing, Inc. (the "TransThera") announced that the new drug application for Tinengotinib tablets has been accepted by the Center for Drug Evaluation ("CDE")of the National Medical Products Administration ("NM...

2025-12-19 09:46 3931

Freda Key C Presents Advanced Recombinant Collagen Delivery Technology at SCC79

Novel Delivery System for High-Molecular-Weight Collagen Advances Anti-Aging Science at the Society of Cosmetic Chemists' Annual Meeting NEW YORK, Dec. 18, 2025 /PRNewswire/ -- Shandong Freda Biotech Co., Ltd. and its medical-aesthetic skincare brand Key C announced the presentation of a novel c...

2025-12-18 22:00 3224

Global study targets dengue as disease threatens nearly half the world's population

LISMORE, Australia, Dec. 18, 2025 /PRNewswire/ -- Thousands of dengue forecasting models have been published, but few have been tested in real public-health settings. Now, researchers from the US andAustralia are launching a field evaluation inVietnam to see whether a new early-warning platform c...

2025-12-18 21:01 3969

VetMew, the AI-powered Pet Health Support App, Officially Launches in North American Market

BOSTON, Dec. 18, 2025 /PRNewswire/ -- VetMew, an AI-powered pet health support application, today announced its official launch in the North American market. The app delivers a groundbreaking tool designed to empower pet owners with immediate, accurate, and personalized AI-driven pet health guida...

2025-12-18 14:58 1888

CorestemChemon Advances Toward ALS Stem Cell Commercialization with Regulatory Progress in Korea and NSF-Backed U.S. Expansion

SEOUL, South Korea, Dec. 17, 2025 /PRNewswire/ -- CorestemChemon (KOSDAQ: 166480)is entering a critical late-stage phase in the commercialization of its ALS stem cell therapy, Neuronata-R. The company attributes this momentum to advanced domestic regulatory review in Korea, entry into an NSF-supp...

2025-12-18 10:31 1994
1 ... 17181920212223 ... 314

Week's Top Stories